Healthcare Global Enterprises Limited Stock Price Today (NSE: HCG)

Healthcare Global Enterprises Limited

699.305.10 (0.72%)
Market Closed

Fundamental Score

...

Healthcare Global Enterprises Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Healthcare Global Enterprises Limited share price today is 699.30, down 0.72% on NSE/BSE as of 2 September 2026. Healthcare Global Enterprises Limited (HCG) is a Mid-cap company in the Hospital sector with a market capitalisation of 9.66K (Cr). The 52-week high for HCG share price is 804.65 and the 52-week low is 513.30. At a P/E ratio of 424.20x, HCG is currently trading above its industry average P/E of 48.79x. The company has a Return on Equity (ROE) of 1.22% and a debt-to-equity ratio of 0.68.

Healthcare Global Enterprises Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
755.00
Low
649.00
Volume
1.8L
Change
+9.17%

Healthcare Global Enterprises Limited share price chart: 9.17% return over the past month. 52-week high ₹804.65, 52-week low ₹513.30.

Healthcare Global Enterprises Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
704.40716.55695.80699.3095.42K (Cr)
735.00737.95701.50704.402.70L (Cr)
695.60775.00687.50733.302.64L (Cr)
703.95704.90693.55696.3054.97K (Cr)
707.00714.00692.30699.951.05L (Cr)
727.00727.00698.15706.1573.82K (Cr)
721.45732.00715.30724.8554.20K (Cr)
725.95729.95710.10718.8085.87K (Cr)
732.00734.80718.35725.9596.29K (Cr)
743.00743.00728.00730.451.21L (Cr)

Healthcare Global Enterprises Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
735.00737.95695.80699.30-4.86%
684.00775.00652.60733.30+7.21%
627.95688.20617.45671.20+6.89%
643.80655.05590.60627.10-2.59%
579.80664.00575.60637.25+9.91%
536.00584.85516.85572.55+6.82%
563.00587.15513.30525.20-6.71%
591.10613.95556.50572.11-3.21%
667.80675.00567.25592.05-11.34%
724.25745.00657.05662.00-8.60%
747.00770.90696.95730.35-2.23%
640.35804.65630.60747.15+16.68%

AI Research Briefing

Powered by Gemini · 2026-04-10

Overvalued cancer play with stretched financials and integration risk; KKR is the only safety net.

Research Confidence
6.0/10Moderate
OPERATOR-DRIVENConsolidation - 1M: -1.09%, 3M: 10.37%, 6M: 33.65%Expensive - P/E 296.22x vs Industry P/E 52.84x

WHAT'S HAPPENING NOW (last 2-4 weeks)

Healthcare Global Enterprises (HCG) completed a rights issue of equity shares aggregating to The equity shares commenced trading on BSE and NSE on April 1, 2026. HCG also received a three-week extension for the Vizag Hospital stake acquisition.

CORE STORY (THE REAL GAME)

HCG is a bet on the growing demand for cancer care in India, fueled by rising incidence and under-penetration of quality treatment. KKR's acquisition of a controlling stake signals confidence in this long-term trend.

Why Now
  • Rights issue completed, reducing immediate funding pressure
  • Vizag Hospital acquisition on track
  • KKR ownership provides stability
Potential Catalysts
  • Faster-than-expected integration of Vizag Hospital
  • Significant improvement in interest coverage ratio
  • New partnerships with international healthcare providers
Key Risks
  • High Debt/Equity ratio of 1.92x
  • Extremely high P/E of 296.22x vs industry average of 52.84x
  • Micro/Small Cap - liquidity risk
Institutional Activity

FII increased stake by 1.43%, DII increased stake by 5.14%, Promoter increased stake by 1.32%.

Macro Context

Healthcare spending in India is increasing, but rupee depreciation could impact costs.

Order Book / Expansion

Acquiring additional 34% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 1.6 billion.

Cash Flow Quality

Yes - Free Cash Flow 5Y: ₹571.13 Cr

3–6 Month Outlook

HCG needs to demonstrate improved profitability and efficient integration of Vizag Hospital in the next 6 months. Failure to do so will expose the stretched valuation.

Primary Thesis Risk

Inability to service debt due to poor profitability will trigger a collapse.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

1.22%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

7.43%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

19.17%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Healthcare Global Enterprises Limited Valuation Check

Poor

Price to Earnings (P/E)

424.20x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

48.79x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

63.78%

% shares held by company founders/management

Poor

FII Holding

2.74%

% shares held by foreign institutional investors

Good

DII Holding

19.20%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

5.17%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

189.89%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

13.36%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

20.22%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.68x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

1.14x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

529.39 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Healthcare Global Enterprises Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of HCG across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Operating Margins (19.17%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (189.89%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Consistent Growth Track Record (20.22% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Cash Generation (₹529.39 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (63.78%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Risk Factors

6 factors identified

Below-Average Return on Equity (1.22%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (7.43%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 424.20x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (7.25x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Weak Interest Coverage (1.14x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Healthcare Global Enterprises Limited vs Hospital Peers

Peer Comparison - Hospital

Compare Healthcare Global Enterprises Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
42.7/100
699
₹9663.25
424.2
Average
1.22%
Poor
7.43%
Poor
0.7
Good
20.22%
Excellent
0.00%
62.1/100
8817
₹128448.55
61.5
Average
21.95%
Excellent
19.28%
Good
0.6
Good
66.81%
Excellent
19.03%
Excellent
0.22%
56.9/100
1014
₹107422.79
73.7
Average
14.33%
Average
13.43%
Average
0.3
Excellent
27.30%
Excellent
0.18%
56.8/100
917
₹73687.64
70.3
Average
11.08%
Average
12.83%
Average
0.3
Excellent
17.76%
Excellent
0.10%
37.2/100
818
₹71917.90
225.7
Average
9.70%
Poor
11.35%
Average
0.2
Excellent
21.31%
Excellent
-11.61%
Poor
0.61%
68.3/100
1803
₹41592.95
51.0
Average
19.74%
Good
14.53%
Average
1.1
Average
25.05%
Excellent
0.22%
59.9/100
1443
₹35993.93
64.7
Average
15.15%
Good
16.85%
Good
0.3
Excellent
0.04%
13.9/100
806
₹33947.05
166.0
Average
11.01%
Average
9.35%
Poor
1.4
Average
3.71%
Average
24.04%
Excellent
0.00%
48.5/100
503
₹15618.15
105.3
Average
6.84%
Poor
10.16%
Average
0.1
Excellent
0.00%
65.5/100
1459
₹15270.28
53.5
Average
17.86%
Good
18.10%
Good
0.0
Excellent
0.23%
60/100
318
₹9829.95
52.3
Average
13.41%
Average
15.25%
Good
0.3
Excellent
0.07%

Healthcare Global Enterprises Limited PE Ratio History

Historical price-to-earnings ratio for HCG — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20253.14₹662.00210.8x
FY 20243.43₹489.15142.6x
FY 20232.10₹365.50174x
FY 20223.97₹287.4572.4x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Healthcare Global Enterprises Limited Quarterly Performance

Latest quarterly metrics for HCG — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

13.36%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

189.89%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

20.22%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Healthcare Global Enterprises Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for HCG — calculated from daily price history

65RSI 14
Neutral — RSI 65

Momentum is balanced — neither overbought nor oversold.

SMA 50
655
▲ Price above SMA 50 — Short-term bullish
SMA 200
640
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
245K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Healthcare Global Enterprises Limited Financial Statements

Annual income statement, balance sheet and cash flow for Healthcare Global Enterprises Limited (HCG) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Healthcare Global Enterprises Limited

Loading latest quarterly results...

About HCG (Healthcare Global Enterprises Limited)

Healthcare Global Enterprises Ltd is a leading institution redefining cancer care within its hospital settings. Stepping inside, one encounters a meticulously designed environment,... intended to foster healing and well-being. The advanced infrastructure houses cutting-edge diagnostic and treatment technologies, from high-resolution imaging suites to specialized operating theaters equipped for complex oncological procedures. A palpable sense of hope permeates the air, amplified by the presence of compassionate medical staff who prioritize patient comfort and understanding. The hospital's architecture emphasizes natural light and open spaces, aiming to minimize anxiety and create a welcoming atmosphere for patients and their families navigating challenging circumstances. Art installations and calming color palettes further contribute to a holistic approach that extends beyond mere physical treatment. Beyond the physical infrastructure, HCG hospitals are hubs of medical innovation and expertise. A multidisciplinary team of oncologists, surgeons, radiologists, and support staff collaborate seamlessly to deliver personalized treatment plans tailored to each patient's unique needs. Research and development are integral components of the hospital's ethos, driving the adoption of novel therapies and techniques. Regular training programs ensure that healthcare professionals stay at the forefront of oncological advancements. Emphasis is placed on precision medicine, utilizing advanced genomic testing and molecular diagnostics to optimize treatment effectiveness while minimizing side effects. This commitment to pioneering approaches positions HCG as a center of excellence in cancer care. The patient experience at HCG hospitals extends far beyond the confines of medical procedures. A comprehensive support system is in place to address the emotional, psychological, and social needs of individuals undergoing cancer treatment. Counseling services, support groups, and palliative care are readily available, fostering a sense of community and shared understanding. The hospital emphasizes open communication and patient empowerment, ensuring that individuals are actively involved in their care decisions. Furthermore, nutritional guidance, rehabilitation programs, and survivorship support are integrated into the treatment journey, promoting long-term well-being and improving the quality of life for patients and their families.

Company Details

Symbol:HCG
Industry:Hospital
Sector:Hospital

Key Leadership

Manisha Kumar
Cluster Head & COO
Ms. Sunu Manuel Abey
Compliance Officer & Company Secretary
Dr. Manish Mattoo
CEO & Executive Director

HCG Share Price: Frequently Asked Questions

What is the current share price of Healthcare Global Enterprises Limited?

Healthcare Global Enterprises Limited (HCG) trades at ₹699.30 on NSE and BSE. Market cap ₹9.66K (Cr). Educational data only.

What is the P/E ratio of Healthcare Global Enterprises Limited?

Healthcare Global Enterprises Limited has a P/E of 424.20x vs industry average 48.79x.

What is the Bull Run score for Healthcare Global Enterprises Limited?

Healthcare Global Enterprises Limited has a Bull Run score of 42.7/100 based on 25+ financial parameters.

Does Healthcare Global Enterprises Limited pay dividends?

Healthcare Global Enterprises Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Healthcare Global Enterprises Limited?

Healthcare Global Enterprises Limited has ROE of 1.22%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Healthcare Global Enterprises Limited?

Healthcare Global Enterprises Limited has debt-to-equity of 0.68.

Is Healthcare Global Enterprises Limited a good investment?

Bull Run gives Healthcare Global Enterprises Limited a score of 42.7/100. This is not investment advice — consult a SEBI-registered advisor.